A video of NORML officials delivering the public comments to the FDA’s Rockville, Maryland, office is available on its Facebook page. In early April 2018, the FDA requested public comments regarding cannabis as a Schedule I drug, grouped with heroin and cocaine, among other drugs. The Washington, D.C.-based cannabis advocacy group, the National Organization for the Reform of Marijuana Laws (NORML) hand-delivered more than 10,000 comments from concerned Americans on Monday, April 23, 2018 to the FDA’s offices in suburban Washington. Comments can be submitted until midnight Monday, April 23, 2018 online. NORML’s efforts account for 61 percent of the total contributions from Americans to the WHO review.
After the Food and Drug Administration (FDA) requested public comments on whether to change marijuana’s classification as a drug with no medical use and a high potential for abuse, a leading US cannabis advocacy group turned in more than 10,000 responses for a survey that could shift drug laws all over the world.
In early April 2018, the FDA requested public comments regarding cannabis as a Schedule I drug, grouped with heroin and cocaine, among other drugs. The World Health Organization (WHO) is conducting a review on international prohibition of cannabis and will consider all of the comments gathered by the FDA in the United States, as well as similar...
Read the full article @ Marijuana